Inhibition of the BcR pathway has revolutionized the treatment landscape of CLL7 and the prognostic difference between U-CLL and M-CLL is diminished in patients treated with BcR inhibitors8. Here, BCR is linked to B-cell chronic lymphocytic leukemia.